15 Participants Needed

Through-flow System for Respiratory Insufficiency

(Throughflow Trial)

JW
JD
R(
Overseen ByRongyu ( Cindy) Jin
Age: 18+
Sex: Any
Trial Phase: Academic
Sponsor: University Health Network, Toronto
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

Trial Summary

What is the purpose of this trial?

Mechanical ventilation can lead to diaphragm and lung injury. During mechanical ventilation, the diaphragm could be completely rested or it could be overworked, either of which may cause diaphragm injury. Mechanical stress and strain applied by mechanical ventilation or by the patient's own respiratory muscles can also cause injury to the lungs. Diaphragm and lung injury are associated with increased morbidity and mortality. Throughflow is a novel system that can reduce dead space without the need to increase the tidal ventilation, reducing the ventilatory demands and respiratory drive.

Will I have to stop taking my current medications?

The trial information does not specify whether you need to stop taking your current medications.

What data supports the effectiveness of the Through-flow System treatment for respiratory insufficiency?

The research on computer-based evaluation systems and transtracheal oxygen administration suggests that tailored and optimized respiratory therapies can improve patient outcomes by ensuring precise oxygen delivery and reducing respiratory effort. These findings imply that the Through-flow System, which likely involves similar optimization and delivery techniques, could be effective in managing respiratory insufficiency.12345

How is the Through-flow System treatment different from other treatments for respiratory insufficiency?

The Through-flow System treatment is unique because it focuses on optimizing the flow of air and gases in the lungs, providing a more detailed analysis of ventilation and gas exchange compared to traditional methods. This approach can offer deeper insights into lung function and help tailor treatments more precisely for patients with respiratory insufficiency.56789

Research Team

EG

Ewan Goligher, MD, PhD

Principal Investigator

University Health Network, Toronto

LD

Lorenzo Del Sorbo

Principal Investigator

University Health Network, Toronto

Eligibility Criteria

This trial is for patients with a specific type of breathing difficulty due to lung or diaphragm injury, who are already on mechanical ventilation. They must have a certain level of oxygenation issues and visible lung problems on imaging tests. It's not for those with high brain pressure, expected to be off the ventilator within a day, recent upper GI surgery, or intubated due to brain injury or stroke.

Inclusion Criteria

I am on a breathing machine through a tube in my mouth.
Your blood oxygen level is too low at the time of screening.
You have cloudy areas in both lungs on a chest X-ray or CT scan.

Exclusion Criteria

I have been diagnosed with high pressure in my brain.
I haven't had upper GI surgery or issues with bleeding in my esophagus/stomach recently.
I was intubated due to a brain injury or stroke.
See 1 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

1-2 weeks

Treatment

Participants receive the Throughflow system to reduce anatomical dead space during mechanical ventilation

24 hours
Continuous monitoring during hospital stay

Follow-up

Participants are monitored for safety and effectiveness after treatment

1 week

Treatment Details

Interventions

  • Throughflow titration phase
Trial Overview The study is testing the Throughflow system which aims to reduce respiratory drive without increasing breath size by removing dead space in mechanically ventilated patients. This could potentially prevent further damage to the lungs and diaphragm caused by overworking during artificial ventilation.
Participant Groups
1Treatment groups
Experimental Treatment
Group I: ThroughflowExperimental Treatment1 Intervention
Throughflow is a novel system that reduces anatomical dead space by providing a constant flow of fresh gas (i.e., gas that is free of CO2) during inspiration in patients receiving invasive mechanical ventilation. By clearing the CO2 that normally remains in the upper airway after exhalation (anatomical dead space), TF can dramatically reduce anatomical dead space without the need to increase the delivered VT, making it a safe strategy in terms of lung protection. This reduction in dead space reduces the ventilatory demands of the patients, reducing respiratory drive.

Find a Clinic Near You

Who Is Running the Clinical Trial?

University Health Network, Toronto

Lead Sponsor

Trials
1,555
Recruited
526,000+

Unity Health Toronto

Collaborator

Trials
572
Recruited
470,000+

Findings from Research

A new computerized system for optimizing Positive End-Expiratory Pressure (PEEP) was developed and tested on six dogs with induced pulmonary injury, demonstrating the ability to reach optimal PEEP levels efficiently, particularly with the FRC normalization algorithm achieving this in just 40 minutes.
This automated noninvasive PEEP titration system can enhance patient care by ensuring that PEEP therapy is continuously optimized, potentially improving outcomes for patients with refractory hypoxemia.
Computer-controlled optimization of positive end-expiratory pressure.East, TD., Andriano, KP., Pace, NL.[2020]
Long-term oxygen treatment (LTOT) significantly improves the prognosis for patients with chronic respiratory insufficiency by enhancing oxygenation, lowering pulmonary artery pressure, and reducing respiratory effort.
Individualized therapy is crucial for LTOT, as patients require tailored solutions that consider their mobility needs and the specific characteristics of different oxygen delivery systems, such as stationary versus mobile devices.
[Long-term oxygen therapy (LTOT)--what should physicians, homecare-providers and health insurance companies know?].Koehler, U., Hildebrandt, O., Jerrentrup, L., et al.[2014]
A new computer-based evaluation system has been developed to assess respiratory dynamics and gas exchange in intubated patients, particularly those suffering from adult respiratory distress syndrome (ARDS) due to trauma or sepsis.
This system allows for real-time data analysis, enabling healthcare providers to tailor ventilatory therapies to individual patient needs, leading to more precise and effective treatment strategies for ARDS.
Computer-based evaluation of cardiopulmonary function for the optimization of ventilatory therapy in the adult respiratory distress syndrome.Siegel, JH., Stoklosa, J., Geisler, FH., et al.[2020]

References

Computer-controlled optimization of positive end-expiratory pressure. [2020]
[Long-term oxygen therapy (LTOT)--what should physicians, homecare-providers and health insurance companies know?]. [2014]
Computer-based evaluation of cardiopulmonary function for the optimization of ventilatory therapy in the adult respiratory distress syndrome. [2020]
Respiratory rehabilitation with transtracheal oxygen system. [2017]
Reliable detection of inspiration and expiration by computer. [2019]
PDPS: a pulmonary data processing system for assessment of gas exchange properties by multiple gas wash-out. [2019]
System to obtain exercise respiratory flow waveforms. [2019]
Device for humidification and controlled oxygenation during spontaneous breathing. [2019]
Cardiac output determination: thermodilution versus a new computerized Fick method. [2013]